Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.
Giulia FerranniniLars H LundLina BensonManfredi RizzoWael AlmahmeedGiuseppe M C RosanoGianluigi SavareseFrancesco CosentinoPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
SGLT2i and DPP-4i use was associated with higher risk of incident severe COVID-19. DPP-4i use was associated with higher 30-day mortality in patients with COVID-19, whereas SGLT2i use was not. No increased risk for any outcome was observed with GLP-1 RA.